Eli Lilly and Company· LLY

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

• 

  This Trend is Excellent News for Eli Lilly and Its Investors

  Eli Lilly dominates the weight loss drug market -- one set to approach $100 billion in a few years. Lilly and rival Novo Nordisk launched weight loss pills this year, and so far, Novo is leading in prescriptions.

  Sep 17, 2026
• 

  15 stocks that have grown dividends the most — and nearly all have beaten the S&P 500

  There is a correlation between increasing dividends and strong investment performance — even if a stock has a low dividend yield when you buy.

  Sep 16, 2026
• 

  Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

  Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

  Sep 16, 2026
• 

  First Look: Fed Rate Hike Looms, Ford Unveils 2027 F-150, Paramount-WBD Antitrust Talks

  Prefer to listen? Hear this as a ~5-minute audio briefing on The GuruFocus Brief.Stock NewsFed poised for first rate hike in three years: The Federal Reserve is

  Sep 16, 2026
• 

  5 Buy-and-Hold Stocks Built to Weather a Volatile Market

  It's impossible to take all the risk out of investing. But that doesn't mean investors can't make a good attempt.

  Sep 16, 2026

• BB

  Berenberg Upgrades Eli Lilly (LLY) to Buy

  Berenberg Bank· Kerry Holford· $1,400.00
  Sep 15, 2026
• WF

  Eli Lilly (LLY) PT Raised to $1,330 at Wells Fargo

  Wells Fargo· Mohit Bansal· $1,330.00
  Aug 6, 2026
• BC

  Eli Lilly (LLY) PT Raised to $1,400 at BMO Capital

  BMO Capital· Evan Seigerman· $1,400.00
  Aug 6, 2026
• MS

  Eli Lilly price target raised to $1,347 from $1,344 at Morgan Stanley

  Morgan Stanley· Terence Flynn· $1,347.00
  Jul 8, 2026
• LP

  Eli Lilly price target raised to $1,232 from $1,119 at Leerink

  Leerink Partners· David Risinger· $1,232.00
  Jun 25, 2026